A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

Required: VTCN1 expression by IHC (testing required; no eligibility threshold specified) (testing required; no eligibility threshold specified)

Tumor tissue ... is required for retrospective detection of B7 homolog 4 (B7-H4) expression by Immunohistochemistry (IHC) in central laboratory and other biomarker analysis.

Allowed: FOLR1 overexpression

Participants with known Folate receptor-α (FR-α) expressing tumors must have received mirvetuximab soravtasine if the participants was considered a candidate for this regimen and the regimen is locally available.

Allowed: BRCA1 mutation

Participants with known Breast cancer susceptibility gene (BRCA) mutated tumors should have received a Poly adenosine diphosphate-ribose polymerase (PARP) inhibitor if the participant was considered a candidate for this regimen and the regimen is locally available.

Allowed: BRCA2 mutation

Participants with known Breast cancer susceptibility gene (BRCA) mutated tumors should have received a Poly adenosine diphosphate-ribose polymerase (PARP) inhibitor if the participant was considered a candidate for this regimen and the regimen is locally available.

Must have received: platinum-based chemotherapy — endometrial cancer cohort

Must have had prior platinum ... if considered a candidate for this regimen and the regimen is locally available.

Must have received: anti-PD-1 therapy — endometrial cancer cohort

Must have had prior ... PD(L)-1 inhibitor (in same regimen or in separate regimens), if considered a candidate for this regimen and the regimen is locally available.

Must have received: bevacizumab (bevacizumab) — PROC cohort

Must have had prior bevacizumab if the participant was considered a candidate for this regimen and the regimen is locally available.

Cannot have received: B7-H4-targeted therapy

Have received any of B7-H4-targeted therapies.

Cannot have received: cytotoxic chemotherapy

Exception: within 28 days prior to the first dose of study drug

Have received any of cytotoxic chemotherapy drugs ... within 28 days prior to the first dose of study drug; or need to continue these drugs during the study.

Cannot have received: topoisomerase inhibitor

Have received prior therapy with topoisomerase inhibitors or topoisomerase inhibitor Antibody-drug conjugate (ADCs)

Cannot have received: antibody-drug conjugate

Have received prior therapy with ... topoisomerase inhibitor Antibody-drug conjugate (ADCs)